Back to Search
Start Over
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
- Source :
- Journal of Antimicrobial Chemotherapy, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2016, 71 (9), pp.2397--2404. ⟨10.1093/jac/dkw157⟩, Journal of Antimicrobial Chemotherapy, 71, 2397-404, Journal of Antimicrobial Chemotherapy, 71, 9, pp. 2397-404, Journal of Antimicrobial Chemotherapy, 2016, 71 (9), pp.2397--2404. ⟨10.1093/jac/dkw157⟩
- Publication Year :
- 2016
- Publisher :
- HAL CCSD, 2016.
-
Abstract
- Contains fulltext : 172373.pdf (Publisher’s version ) (Closed access) The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.
- Subjects :
- 0301 basic medicine
Microbiology (medical)
Antifungal Agents
[SDV]Life Sciences [q-bio]
030106 microbiology
Pneumocitis jirovecii
Chemoprevention
Trimethoprim
Immunocompromised Host
03 medical and health sciences
0302 clinical medicine
Trimethoprim, Sulfamethoxazole Drug Combination
Humans
Pharmacology (medical)
Pharmacology
Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]
Sulfamethoxazole Drug Combination
Pneumocystis
Hematologic Neoplasms
Pneumonia, Pneumocystis
Stem Cell Transplantation
Transplant Recipients
Infectious Diseases
immunocomrpomised host, pneumonia, Pneumocitis jirovecii
Pneumonia
3. Good health
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
030220 oncology & carcinogenesis
immunocomrpomised host
Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Subjects
Details
- Language :
- English
- ISSN :
- 03057453 and 14602091
- Database :
- OpenAIRE
- Journal :
- Journal of Antimicrobial Chemotherapy, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2016, 71 (9), pp.2397--2404. ⟨10.1093/jac/dkw157⟩, Journal of Antimicrobial Chemotherapy, 71, 2397-404, Journal of Antimicrobial Chemotherapy, 71, 9, pp. 2397-404, Journal of Antimicrobial Chemotherapy, 2016, 71 (9), pp.2397--2404. ⟨10.1093/jac/dkw157⟩
- Accession number :
- edsair.doi.dedup.....38eaaa9ed613c59da4242367ee07f835